Lou Tartaglia
Founder at Cure Ventures Management LP
Profile
Dr. Tartaglia (Lou) is a Managing Partner and Co-Founder of Cure Ventures.
Lou’s career spans more than 30 years demonstrating scientific and therapeutic product project leadership within the biotech industry as well as investment leadership within multiple venture capital firms.
His experience and skills as a rigorous scientist have manifested itself across a wide array of functional areas, allowing him to serve with distinction within the C-Suite in numerous biotech start-ups.
In 2016 Lou served as Head of 4:59, 5AM Venture’s internal de novo new company formation initiative.
In that first year he led the formation of Entrada Therapeutics (NASDAQ: TRDA) and then served as interim CEO for its first year.
Lou subsequently transitioned into a 5AM Venture Partner role where he has taken CEO roles at start-ups.
From 2007 to 2014 Lou served as a Partner at Third Rock Ventures where he played an integral role in the overall scientific diligence, formation, and development of its portfolio companies.
While a Partner at Third Rock he played crucial roles in starting many of Third Rock’s most successful portfolio companies including as Chief Scientific Officer of Editas (NASDAQ: EDIT), Rhythm (NASDAQ: RYTM) and Agios (NASDAQ: AGIO) for the first year of operations.
Beyond Third Rock he also served as Chief Executive Officer of Solstice Biologics and General Manager at GeneLogic.
Lou was formerly the first employee of and Vice President at the start-up Millennium Pharmaceuticals where he was responsible for the discovery and development of multiple therapeutic programs, which was later acquired for $8.7 Billion by Takeda Pharmaceuticals.
Lou completed his postdoctoral work at Genentech in the laboratory of Dr. David Goeddel.
He received his Ph.D.
in Biochemistry at the University of California, Berkeley in the laboratory of Dr. Bruce Ames and his B.S.
in Chemistry at the State University of New York at Albany.
Lou Tartaglia active positions
| Companies | Position | Start |
|---|---|---|
Cure Ventures Management LP
 Cure Ventures Management LP Investment ManagersFinance Cure Ventures Management LP (Cure Ventures) is a venture capital firm founded in 2021 by David R Fallace, Richard J Lim and Lou A Tartaglia. The firm is headquartered in Boston, Massachusetts. | Founder | 2021-06-30 |
Former positions of Lou Tartaglia
| Companies | Position | End |
|---|---|---|
5AM Venture Management LLC
 5AM Venture Management LLC Investment ManagersFinance 5AM Venture Management LLC (5AM Ventures) is an Independent Venture Capital firm founded in 2002 by Andrew J. Schwab, Carin M. Rollins and John D. Diekman. The firm is headquartered in San Francisco, US. | Private Equity Investor | 2020-10-30 |
| LARIMAR THERAPEUTICS, INC. | Director/Board Member | 2014-06-01 |
Gene Logic, Inc.
 Gene Logic, Inc. BiotechnologyHealth Technology Gene Logic, Inc. provides drug discovery and development services to pharmaceutical and biotechnology companies worldwide. The company operates in three segments: Genomics and Toxicogenomics Services, Preclinical Contract Research Services, and Drug Repositioning and Selection Services. Gene Logic was incorporated in 1994 and is headquartered in Gaithersburg, Maryland. | Corporate Officer/Principal | 2007-06-17 |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 2004-05-31 |
| ENTRADA THERAPEUTICS, INC. | Director/Board Member | - |
Training of Lou Tartaglia
| University of California, Berkeley | Doctorate Degree |
| State University of New York at Albany | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| AGIOS PHARMACEUTICALS, INC. | Health Technology |
| EDITAS MEDICINE, INC. | Health Technology |
| ENTRADA THERAPEUTICS, INC. | Health Technology |
| Private companies | 10 |
|---|---|
Gene Logic, Inc.
Gene Logic, Inc. BiotechnologyHealth Technology Gene Logic, Inc. provides drug discovery and development services to pharmaceutical and biotechnology companies worldwide. The company operates in three segments: Genomics and Toxicogenomics Services, Preclinical Contract Research Services, and Drug Repositioning and Selection Services. Gene Logic was incorporated in 1994 and is headquartered in Gaithersburg, Maryland. | Health Technology |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Finance |
Zafgen, Inc.
 Zafgen, Inc. BiotechnologyHealth Technology Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA. | Health Technology |
Ablexis LLC
 Ablexis LLC Packaged SoftwareTechnology Services Ablexis LLC develops next-generation platform for antibody drug discovery. It develops the AlivaMab Mouse, an innovative, next-generation transgenic mouse platform intended to enable the efficient discovery and development of the next generation of human therapeutic antibodies. The company was founded by Green L. Larry and Hiroaki Shizuya in December 2009 and is headquartered in Burlingame, CA. | Technology Services |
Ember Therapeutics, Inc. /Old/
 Ember Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Ember Therapeutics, Inc. provides treatment for metabolic disorders and obesity diseases. Its products target brown fat biology and mechanisms of selective insulin sensitization. The company was founded by Bruce M. Spiegelman, Patrick R. Griffin and Ronald C. Kahn in 2011 and is headquartered in New York, NY. | Health Technology |
Allergan GI Corp.
 Allergan GI Corp. BiotechnologyHealth Technology Allergan GI Corp. develops peptide therapeutics for the treatment of gastrointestinal disorders. It provides RM-493 a small-peptide melanocortin-4 receptor agonist, for the treatment of obesity and diabetes, and RM-131 a small-peptide ghrelin agonist, for the treatment of diabetic gastro paresis and other gastrointestinal functional disorders. The company was founded by Bart Henderson and Elizabeth Stoner in 2008 and is headquartered in Madison, NJ. | Health Technology |
Solstice Biologics LLC
 Solstice Biologics LLC Pharmaceuticals: MajorHealth Technology Solstice Biologics LLC develops nucleic acid therapeutics. It specializes in the development of small, cell-permeable RNAi pro-drugs. The company was founded by Steven Dowdy and Curt W. Bradshaw in 2012 and is headquartered in San Diego, CA. | Health Technology |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
5AM Venture Management LLC
5AM Venture Management LLC Investment ManagersFinance 5AM Venture Management LLC (5AM Ventures) is an Independent Venture Capital firm founded in 2002 by Andrew J. Schwab, Carin M. Rollins and John D. Diekman. The firm is headquartered in San Francisco, US. | Finance |
Cure Ventures Management LP
Cure Ventures Management LP Investment ManagersFinance Cure Ventures Management LP (Cure Ventures) is a venture capital firm founded in 2021 by David R Fallace, Richard J Lim and Lou A Tartaglia. The firm is headquartered in Boston, Massachusetts. | Finance |
- Stock Market
- Insiders
- Lou Tartaglia
